OLMA News and Press, Olema Pharmaceuticals Inc. From 07/21/22

SAN FRANCISCO, July 21, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to OP-1250, the Company's novel, oral ...

BMEZ has been getting hit significantly, with the biotech and growth space moving sharply lower. Despite these pressures, I believe that BMEZ is attractive given its current discount and selloff. With our recent update on BlackRock Science & Technology Trust II, the fund's dis...

Olema Pharmaceuticals (NASDAQ:OLMA) on Thursday announced a clinical update for its lead candidate OP-1250 for the treatment of metastatic breast cancer. In its phase 1b dose expansion of OP-1250 as a monotherapy, OLMA said it observed favorable tolerability in the 30 patients enrolled. OLMA ...

Favorable tolerability with no grade 3/4 neutropenia and encouraging anti-tumor activity across Phase 1b monotherapy expansion Combinability with CDK4/6i palbociclib demonstrated across initial dose escalation cohorts, including no dose limiting toxicities and no induced metab...

SAN FRANCISCO, June 09, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA) and Aurigene Discovery Technologies Limited (“Aurigene”) today announced an exclusive global license agreement to research, ...

SAN FRANCISCO, May 24, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women...

Olema Pharmaceuticals press release (NASDAQ:OLMA): Q1 GAAP EPS of -$0.58. Cash, cash equivalents and marketable securities as of March 31, 2022, were $267.9 million. For further details see: Olema Pharmaceuticals GAAP EPS of -$0.58

Phase 1/2 trial of OP-1250 continues to enroll patients in the dose expansion stage, with selection of Recommended Phase 2 Dose expected in Q2 2022 Phase 1b combination study with palbociclib ongoing; Additional combination trials with CDK4/6 and PI3K α inhibitors...

Gainers: Checkmate Pharmaceuticals (CMPI) +332%. Sono Group (SEV) +66%. ToughBuilt Industries (TBLT) +55%. Petros Pharmaceuticals (PTPI) +40%. Axsome Therapeutics (AXSM) +25%. Cyren (CYRN) +22%. Super Micro Computer (SMCI) +21%. Pulse Biosciences (PLSE) +18%. Annexon (ANNX) +18%. Olema Pharma...

SAN FRANCISCO, April 18, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema,” “Olema Oncology” or the “Company,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of ...